Cloud Banner

Pharmaceutical

Image

Global Allergic Asthma Disease Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Allergic Asthma Disease Market, By Drug Class (Inhaled Corticosteroids, Anticholinergics, Beta Agonists, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Allergic Asthma Disease Market

Allergic Asthma Disease Market Analysis and Size

The global allergic asthma disease market is expected to witness significant growth during the forecast period. The growth of allergic asthma disease market is rise by the high prevalence of indoor as well as outdoor allergen that causes asthma disease.  The allergic asthma disease market growth is immensely impacted by the sudden outbreak of COVID-19 all across the globe.

 Data Bridge Market Research analyses a growth rate in the global allergic asthma disease market in the forecast period 2022-2029. The expected CAGR of global allergic asthma disease market is tend to be around 3% in the mentioned forecast period. The market was valued at USD 7 billion in 2021, and it would grow upto USD 8.87 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

When the asthma is caused due to certain allergen such as tobacco smoke, dust mites, pollen, or air pollution, it results in allergic asthma. The typical sign and symptoms of the allergic asthma are recurrent episodes of breathlessness and wheezing.           

Allergic Asthma Disease Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Inhaled Corticosteroids, Anticholinergics, Beta Agonists, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Sunovion Pharmaceuticals Inc. (U.S.), AbbVie Inc (U.S.)

Market Opportunities

  • Increasing Demand for Retail Pharmacies
  • Rising Healthcare Expenditure

Global Allergic Asthma Disease Market Dynamics

Drivers

  • Increased Clinical Acquisitions

Major market players in the industry are strategically expanding to strengthen their position in the global market. For instance, in May 2019, ASLAN Pharmaceuticals amended its license agreement with CSL Limited (CSL) with an aim to have global rights to develop, manufacture, and commercialize ‘ASLAN004’ for all types of indications. ASLAN004 is a fully human monoclonal antibody that helps trigger allergic asthma symptoms such as wheezing, exacerbations of the disease, coughing, and shortness of breath. 

  • Launch of New Drugs

There has been several approvals and launch of novel drugs in the market which boost the market growth during the forecast period. For instance, Teva Pharmaceuticals Industries Limited received U.S. FDA approval in June 2017, for its two products of asthma inhalers namely; ArmonAirTM RespiClick and AirDuoTM Respiclick. These products are very much applicable for adolescent and adult patients who are suffering from asthma. The approved strength of AirDuo is 232/14 mcg, 113/14 mcg, and 55/14 mcg, whereas, the approved strengths of ArmonAir is 232 mcg, 113, mcg, and 55 mcg respectively and recommended as one inhalation twice daily. This boosts the market growth

Opportunities

  • Increasing Demand for Retail Pharmacies

Rise in the number of rhinitis therapeutics are delivered through retail pharmacies and rise in the number of retail pharmacies in developed countries create much opportunities for the market growth. In addition to this, patients select retail pharmacies for purchasing drugs, as these are easily accessible.

  • Rising Healthcare Expenditure

Since the last few decades, it has been witnessed that global per capita healthcare spending has improved considerably due to rising rate of awareness associated with the availability of treatments and diagnostic methods for treating various diseases. More and more healthcare spending is likely to result in increasing demand for better diagnostic methods, which in turn, create high growth opportunities for market players operating in the treatment of allergic and asthmatic conditions in the global allergic asthma disease market.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global allergic asthma disease market over a forecast period.

  • High Cost

The huge expenditure associated with the treatment of allergic asthma surely hamper the market growth.

This global allergic asthma disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global allergic asthma disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Allergic Asthma Disease Market Scope

The global allergic asthma disease market is segmented on the basis of drug class, route of administration , distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Inhaled Corticosteroids
  • Anticholinergics
  • Beta Agonists
  • Others

Route of Administration

  • Oral
  • Inhalation
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Allergic Asthma Disease Market Regional Analysis/Insights

The global allergic asthma disease market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global allergic asthma disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global allergic asthma disease market throughout the forecasted period due to the presence of key generic pharmaceuticals companies in this region and rise in consumption of tobacco products.

North America dominates the market due to the high prevalence of asthma disease and large availability of treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Allergic Asthma Disease Market Share Analysis

The global allergic asthma disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global allergic asthma disease market

Key players operating in the global allergic asthma disease market include:

  • Pfizer Inc.(U.S.)
  • Merck KGaA (Germany)
  • Sanofi (France)
  • Biocare Medical, LLC (U.S.)
  • Lilly (U.S.)
  • Teva Pharmaceutical Industries (Israel)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • Lilly (U.S.)
  • AstraZeneca (U.K.)
  • Sunovion Pharmaceuticals Inc. (U.S.)
  • AbbVie Inc (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The global allergic asthma disease market is projected USD 8.87 billion by 2029.
The global allergic asthma disease market is projected to grow at a CAGR of 3.00% during the forecast period of 2022-2029.
The major players operating in the Allergic Asthma Disease Market are Pfizer Inc.(U.S.), Merck KGaA (Germany), Sanofi (France), Biocare Medical, LLC (U.S.), Lilly (U.S.), Teva Pharmaceutical Industries (Israel), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (U.S.), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Sunovion Pharmaceuticals Inc. (U.S.), AbbVie Inc (U.S.).
The major countries covered in the Allergic Asthma Disease Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials